Cross icon
Contact us
November 17, 2022

The equity investment of Fondation Arthritis

We are pleased to announce the equity investment of Fondation Arthritis in our company to support the clinical development of our disease-modifying osteoarthritis drug candidate.

“As a French start-up focusing on the development of 4P004, a first-in-class Disease Modifying Osteoarthritis Drug (DMOAD) the support of the institution anchoring like the Fondation Arthritis is undeniably important for scientific research and for patients.” said Prof. francis berenbaum, co-founder and CEO/CMO of 4Moving Biotech, Professor at Sorbonne University and head of the rheumatology department at St-Antoine Hospital (AP-HP) in Paris.

Last month, 4Moving Biotech has enrolled its first patient for phase I of LASARE clinical trial study.

For more information:

See the original article